Clover Health names Peter Kuipers as CFO; targets adjusted EBITDA profitability in 2024

CLOVER HEALTH INVESTMENTS, CORP. /DE

Peter Kuipers appointed CFO effective after Q1 2024 10-Q filing; succeeds interim CFO Terrence Ronan.
Kuipers previously CFO at Omnicell (OMCL), helped grow revenue from $485M to $1.3B.
Employment terms: base salary $525k, target bonus 95% of base, $5M RSU grant (25% vest 1yr, remainder quarterly).
Company reiterates goal to achieve adjusted EBITDA profitability in 2024.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Peter Kuipers

Chief Financial Officer

CLOV · CLOVER HEALTH INVESTMENTS, CORP. /DE

Successor: Terrence Ronan
Filed: April 22, 2024, 7:59 PM ET

On April 22, 2024, Clover Health Investments, Corp. (the “Company”) announced that Peter Kuipers will become Chief Financial Officer of the Company, to serve as the Company’s principal financial officer and principal accounting officer, effective as of the day after the filing of the Company’s Quarterly Report on Form 10-Q for the quarter-ended March 31, 2024, as approved by the Board of Directors of the Company on April 16, 2024.

Departed (interim)

Terrence Ronan

Interim Chief Financial Officer

CLOV · CLOVER HEALTH INVESTMENTS, CORP. /DE

Successor: Peter Kuipers
Filed: April 22, 2024, 7:59 PM ET

Mr. Kuipers will succeed Terrence Ronan, the Company’s current Interim Chief Financial Officer, who will continue in his role as Interim Chief Financial Officer until Mr. Kuipers becomes Chief Financial Officer, and thereafter cease to serve as the Company’s principal financial officer and principal accounting officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Peter Kuipers was appointed as Chief Financial Officer at CLOVER HEALTH INVESTMENTS, CORP. /DE.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On April 22, 2024, Clover Health Investments, Corp. (the “Company”) announced that Peter Kuipers will become Chief Financial Officer of the Company, to serve as the Company’s principal financial officer and principal accounting officer, effective as of the day after the filing of the Company’s Quarterly Report on Form 10-Q for the quarter-ended March 31, 2024, as approved by the Board of Directors of the Company on April 16, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Terrence Ronan departed as Interim Chief Financial Officer at CLOVER HEALTH INVESTMENTS, CORP. /DE.

Action: cease to serve
Role: Interim Chief Financial Officer

Exact text from the filing

Mr. Kuipers will succeed Terrence Ronan, the Company’s current Interim Chief Financial Officer, who will continue in his role as Interim Chief Financial Officer until Mr. Kuipers becomes Chief Financial Officer, and thereafter cease to serve as the Company’s principal financial officer and principal accounting officer.

View on SEC.gov

CLOVER HEALTH INVESTMENTS, CORP. /DE filing history →

Source: SEC EDGAR

accession 0001801170-24-000089

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.